Table 3: Univariate analysis of overall survival for C-HCC and NC-HCC patients.
Variables |
Univariate analysis |
|||||
C-HCC |
NC-HCC |
|||||
P value |
HR |
95%Cl |
P value |
HR |
95% Cl |
|
Age years: <65 vs. >65 |
0.121 |
0.815 |
0.628-1.056 |
0.915 |
0.945 |
0.506-1.840 |
Gender: male vs. female |
0.27 |
0.821 |
0.99-1.045 |
0.883 |
0.951 |
0.484-1.867 |
BMI |
0.22 |
1.017 |
0.806-1.431 |
0.047 |
0.929 |
0.863-0.999 |
Diabetes: Yes vs. No |
0.138 |
0.813 |
0.619-1.069 |
0.377 |
0.725 |
0.373-1.408 |
Surveillance : Yes vs. No |
<0.001 |
2.321 |
1.760-3.061 |
0.548 |
0.779 |
0.344-1.763 |
Etiology |
0.543 |
1.021 |
.955-1.091 |
0.443 |
1.052 |
0.925-1.197 |
Extrahepatic metastasis: Yes vs. No |
<0.001 |
0.256 |
0.173-0.377 |
0.247 |
0.631 |
0.289-1.375 |
Portal vein invasion: Yes vs. No |
<0.001 |
0.153 |
0.107-.219 |
0.213 |
0.549 |
.214-1.410 |
BCLC stage |
<0.001 |
2.289 |
2.010-2.607 |
0.028 |
1.655 |
1.057-2.591 |
Treatment |
<0.001 |
1.602 |
1.463-1.756 |
<0.001 |
1.348 |
1.143-1.589 |
C-HCC: Cirrhotic Hepatocellular Carcinoma Group; NC-HCC: Non-Cirrhotic Hepatocellular Carcinoma Group, BMI: Body Mass Index (cm /kg2); BCLC: Barcelona Clinic Liver Cancer; 95% Cl: Confidence Interval.